Tekla Capital Management’s Novo Nordisk NVO Stock Holding History

Tekla Capital Management’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$19.9M	Buy	245,554 +22,908	+10%	+$1.87M	0.78%	36
2023 Q1	$17.7M	Sell	222,646 -38,400	-15%	-$2.72M	0.67%	38
2022 Q4	$17.7M	Hold	261,046	–	–	0.67%	39
2022 Q3	$13M	Hold	261,046	–	–	0.53%	45
2022 Q2	$14.5M	Sell	261,046 -46,000	-15%	-$2.55M	0.57%	48
2022 Q1	$17M	Buy	307,046 +70,348	+30%	+$3.61M	0.6%	47
2021 Q4	$13.3M	Buy	236,698 +45,292	+24%	+$2.45M	0.43%	54
2021 Q3	$9.19M	Buy	191,406 +94,594	+98%	+$4.57M	0.3%	76
2021 Q2	$4.05M	Hold	96,812	–	–	0.13%	129
2021 Q1	$3.26M	Sell	96,812 -33,000	-25%	-$1.18M	0.11%	141
2020 Q4	$4.53M	Sell	129,812 -138,198	-52%	-$4.78M	0.16%	122
2020 Q3	$9.3M	Hold	268,010	–	–	0.35%	68
2020 Q2	$8.78M	Hold	268,010	–	–	0.33%	63
2020 Q1	$8.07M	Sell	268,010 -174,718	-39%	-$5.2M	0.36%	53
2019 Q4	$12.8M	Sell	442,728 -39,272	-8%	-$1.09M	0.48%	43
2019 Q3	$12.5M	Hold	482,000	–	–	0.54%	45
2019 Q2	$12.3M	Sell	482,000 -21,200	-4%	-$524K	0.5%	48
2019 Q1	$13.2M	Sell	503,200 -100,600	-17%	-$2.47M	0.53%	43
2018 Q4	$13.9M	Hold	603,800	–	–	0.6%	39
2018 Q3	$14.2M	Buy	603,800 +332,000	+122%	+$8.1M	0.52%	46
2018 Q2	$6.27M	Hold	271,800	–	–	0.24%	84
2018 Q1	$6.69M	Sell	271,800 -271,800	-50%	-$7.14M	0.26%	83
2017 Q4	$14.6M	Buy	543,600 +396,400	+269%	+$10.1M	0.56%	40
2017 Q3	$3.54M	Sell	147,200 -287,400	-66%	-$6.49M	0.13%	98
2017 Q2	$9.32M	Buy	434,600 +268,600	+162%	+$5.42M	0.35%	60
2017 Q1	$2.85M	Buy	+166,000	New	+$2.89M	0.11%	98
2016 Q2	–	Sell	-589,200	Closed	-$16M	–	162
2016 Q1	$16M	Hold	589,200	–	–	0.68%	34
2015 Q4	$17.1M	Hold	589,200	–	–	0.62%	33
2015 Q3	$16M	Buy	+589,200	New	+$16.7M	0.57%	37

Other funds holding NVO

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Tekla Capital Management's NVO Position: Q2 2023 in Review

Tekla Capital Management increased its Novo Nordisk (NVO) stake by 10% in Q2 2023, buying an estimated $1.87M and bringing the position to 245,554 shares worth $19.9M. The position accounts for 0.78% of the portfolio, ranked #36.

Tekla Capital Management first reported a position in NVO in Q3 2015 and has held it in 29 quarters since. 1,196 funds tracked by Wall St. Rank hold NVO as of Q2 2023.

Tekla Capital Management held 245,554 shares of Novo Nordisk worth $19.9M as of Q2 2023.
Tekla Capital Management bought 22,908 Novo Nordisk shares in Q2 2023, an estimated $1.87M.
Novo Nordisk made up 0.78% of Tekla Capital Management's portfolio in Q2 2023, its #36 holding.
Tekla Capital Management first reported a position in Novo Nordisk in Q3 2015 and has held it in 29 quarters since.
1,196 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.